Zum Inhalt springen

We would like to thank our sponsors this year for their support in making the 6th International Conference On Pediatric Liver Disease a reality.

Your CPLD Organising Team

Our Sponsors 2023


Ipsen is a global, mid-sized biopharmaceutical company
focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and 
development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,400 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). 

For more information, visit www.ipsen.com

Homepage: www.ipsen.com

18.000,- €

Mirum Pharmaceuticals, Inc.

At Mirum, our mission is to create transformative medicine for patients with rare cholestatic liver diseases and, in turn, provide hope for patients and their families.

Homepage: https://mirumpharma.com/

18.000,- €

Theravia (ex. Laboratoires CTRS)

Theravia is a leading international pharmaceutical company specialised in rare or neglected diseases. Formed through the merger of Addmedica and CTRS, we are dedicated to address the unmet medical needs of patients with these challenging conditions. With a deep understanding of the unique challenges faced by individuals affected by rare diseases, we bring together the expertise and resources of Addmedica and CTRS to pioneer innovative therapies. One of our aera of expertise if rare liver disease, with the commercialization of a therapy for two ultra-rare bile acid synthesis defects.

Homepage: https://ctrs.fr/



Dipharma Arzneimittel GmbH is the German subsidiary of the Swiss Dipharma SA, an emerging and modern company, passionate about the needs and well-being of people with rare metabolic disorders. At Dipharma, we strive to develop and manufacture the best products in terms of quality, e.g. for phenylketonuria, hereditary tyrosinemia type 1, Gaucher disease, Niemann-Pick type C disease and urea cycle disorders. We are driven by strong professional ethics, and we do our best to be a reliable and trustworthy partner. Dipharma Arzneimittel GmbH is based in Limburg/Lahn, Germany.

Homepage: https://www.dipharma-arzneimittel.de


Astellas Pharma Inc.

Astellas is a pharmaceutical company committed to turning innovative science into value for patients. Changing tomorrow is the ethos that guides everything we do. Across our areas of therapeutic expertise, we use our agility to match scientific breakthroughs to the
unmet medical needs of people around the world, and the many healthcare professionals and caregivers who support them.
Astellas invests in new medicines, technologies and therapeutic areas, and builds partnerships and networks with others who share our vision to improve the future of medicine.
Astellas is working at the forefront of healthcare change and the values of patient focus, ownership,
results, openness and integrity are the foundation of our culture.

Homepage: https://www.astellas.com/